IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $3.05B
• Dividend Yield: N/A
• Average Volume (3M): 831.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: 5376.27%
• EPS Growth: 20.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.47
• Shares Outstanding: 87,666,405
• 10 Day Avg. Volume: 783,430
• 30 Day Avg. Volume: 831,615
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.88
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 12.20
• Enterprise Value/Gross Profit: 12.43
• Enterprise Value/Ebitda: -16.72
• 1Y Price Target: $51.37
• Price Target Upside: 52.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $39.00 ▲(15.90% Upside)

The score is supported primarily by a strong balance sheet and improving revenue profile, plus bullish technical momentum. It is held back by persistent operating losses and negative free cash flow, with mixed corporate-event impact (pipeline progress offset by the GSK collaboration termination).

Positive Factors

Balance sheet strength

IDEAYA's very low leverage and sizable equity provide durable financial flexibility to fund expensive clinical programs and absorb clinical/regulatory timing risk. Strong capitalization reduces near-term refinancing pressure and supports strategic optionality for partnerships or selective M&A.

Diversified late-stage pipeline

Advancing multiple registrational trials across darovasertib, ADCs and MTAP-pathway programs spreads clinical risk and increases probability of a commercial readthrough. A diversified, progressing pipeline supports a sustained franchise build in precision oncology beyond any single program outcome.

Material revenue step-up and strong gross profit

A sharp revenue increase with strong gross profit suggests improving commercial or partnership revenue traction, reducing sole dependence on financing. Durable top-line growth supports reinvestment in trials and commercial readiness, helping bridge to potential long-term sustainability if losses narrow.

Negative Factors

Negative free cash flow

Sustained negative operating and free cash flow implies ongoing cash burn that can necessitate external financing or dilution to sustain R&D and commercialization. Even with improvement versus prior year, persistent negative FCF is a structural constraint on self-funded growth and strategic flexibility.

Persistent operating losses / negative ROE

Large, ongoing operating losses and a deeply negative ROE indicate the business is not yet generating returns on equity. This undermines internal capital generation, elevates dependence on external funding, and makes successful clinical outcomes essential to materially improve shareholder economics.

GSK collaboration termination risk

The termination and inbound transfer of Werner helicase and Pol Theta programs creates strategic and executional burdens: IDEAYA must reallocate resources, re-evaluate development paths, and potentially incur added costs and timelines to advance or partner these programs, increasing near-term program risk.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company engages in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, research funding, and milestone payments as products progress through various stages of development. Additionally, royalties from product sales may contribute to revenue once therapies are commercialized. The company also focuses on obtaining grants and funding from government and private entities to support its research initiatives, enhancing its financial stability and growth potential.

IDEAYA Biosciences Financial Statement Overview

Summary

Balance sheet strength (low leverage and sizable equity) is a major positive, but it is offset by continued deep losses and negative free cash flow (ongoing cash burn), keeping overall financial performance only moderate for risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue surged to ~$214.8M, a sharp step-up versus prior years, and reported gross profit remains very strong. However, profitability is still deeply negative: TTM net income is about -$160.7M and operating losses remain significant, indicating the business is not yet close to self-funding and results can be volatile quarter-to-quarter.

Balance Sheet

The balance sheet is a clear strength with very low leverage (TTM debt-to-equity ~0.03) and sizable equity (~$1.09B) supporting the asset base (~$1.19B). The main weakness is ongoing negative returns on equity (TTM ROE ~-31%), reflecting continued losses despite strong capitalization.

Cash Flow

Cash generation is weak: TTM operating cash flow is about -$102.3M and free cash flow about -$105.4M, both negative, implying continued cash burn. While cash burn improved versus 2024 (operating cash flow was -$247.6M), free cash flow growth remains meaningfully negative, and the company still depends on existing balance sheet resources and/or external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.83M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	210.79M	3.17M	19.38M	48.83M	26.22M	18.16M
EBITDA	-156.70M	-270.64M	-108.95M	-56.55M	-48.04M	-33.11M
Net Income	-160.74M	-274.48M	-112.96M	-58.66M	-49.76M	-34.49M
Balance Sheet
Total Assets	1.19B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	786.89M	676.32M	525.11M	364.83M	246.77M	283.58M
Total Debt	27.25M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	93.10M	64.94M	28.23M	38.51M	79.83M	100.00M
Stockholders Equity	1.09B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-105.39M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-102.26M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-29.61M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	30.40M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 33.65
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Neutral. The current price of 33.65 is below the 20-day moving average (MA) of 35.62, below the 50-day MA of 34.85, and above the 200-day MA of 26.49, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 11.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDYA	63 Neutral	$3.05B	-18.14	-14.15%	―	5376.27%	20.97%
ARQT	60 Neutral	$3.23B	-71.79	-28.17%	―	129.21%	80.35%
TVTX	56 Neutral	$2.69B	-27.92	-410.78%	―	114.22%	77.02%
CELC	56 Neutral	$5.43B	-31.20	-122.04%	―	―	-40.75%
BEAM	53 Neutral	$3.12B	-6.54	-47.19%	―	-84.07%	-157.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AGIO	49 Neutral	$1.67B	-4.07	-27.57%	―	36.26%	-158.98%

IDEAYA Biosciences Corporate Events

IDEAYA updates precision oncology strategy at JPM 2026

On January 12, 2026, IDEAYA Biosciences posted an updated corporate presentation for investors in connection with the JPM 2026 Annual Healthcare Conference, outlining its strategy to build a leading precision oncology franchise and detailing progress across its diversified clinical pipeline. The presentation highlighted a deep portfolio that includes darovasertib for uveal melanoma approaching a planned Phase 3 initiation in the first half of 2026, MTAP-pathway programs IDE397 and IDE892, antibody drug conjugate and DNA damage repair combinations such as IDE705 and IDE849, and next-generation agents targeting Werner helicase, KAT6/7, and other difficult-to-drug targets, underscoring IDEAYA’s intent to expand its reach across multiple solid tumor indications and strengthen its competitive position in precision oncology.

The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA sets 2026 objectives to advance registrational trials

On January 11, 2026, IDEAYA Biosciences outlined its 2026 corporate objectives, highlighting plans to advance four registrational trials, including darovasertib across the uveal melanoma disease continuum and IDE849 as a monotherapy in neuroendocrine cancers, with key clinical milestones expected throughout the year. The company aims to deliver topline progression-free survival data in the first quarter of 2026 from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2‑negative metastatic uveal melanoma, complete or initiate additional Phase 3 and Phase 2 trials across metastatic, neoadjuvant, and adjuvant settings, and progress multiple ADC and MTAP-pathway programs into early-stage clinical studies, while emphasizing that its approximately $1.1 billion in cash and securities as of September 30, 2025 is expected to fund operations into 2030 and support global commercial readiness efforts with Servier for darovasertib.

The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA Biosciences Faces Collaboration Termination by GSK

On December 9, 2025, GlaxoSmithKline notified IDEAYA Biosciences of its decision to terminate their collaboration and license agreement, effective March 9, 2026. During the transition period, GSK will transfer two clinical programs back to IDEAYA, which will assess its strategic options for these programs in 2026, without affecting its cash runway expectations into 2030.

The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences

On December 4, 2025, GlaxoSmithKline announced its decision to terminate its collaboration with IDEAYA Biosciences, effective ninety days from the notice. During this transition period, GSK will transfer the Werner Helicase and Pol Theta clinical programs back to IDEAYA, which plans to evaluate strategic options for these programs in 2026, maintaining its cash runway expectations into 2030.

The most recent analyst rating on (IDYA) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA Biosciences Presents Promising Phase 2 Data

On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.

The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.